Drug Trial Radar · NCT07780604
A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Nov 18, 2024
Primary completion
Sep 18, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- Galimedix Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of GAL-101 salt following oral administration to healthy adult and elderly participants. A total of 92 participants were enrolled at a single study center. The study consisted of five parts. Part 1 evaluated single ascending doses of enteric-coated GAL-101 capsules compared with placebo in healthy adults. Part 2 compared a single dose of enteric-coated GAL-101 capsules with uncoated GAL-101 salt mixed with apple sauce in an open-label crossover design. Part 3 evaluated the effect of fasting, a standard meal, and a high-fat, high-calorie meal on the pharmacokinetics of a single dose of uncoated GAL-101 salt in an open-label crossover design. Part 4 evaluated multiple ascending doses of uncoated GAL-101 salt administered once daily for 7 days compared with placebo. Part 5 evaluated the pharmacokinetics of a single dose of uncoated GAL-101 salt compared with placebo in healthy elderly participants aged 65 to 85 years.
Conditions
- Healthy Adult Participants
Interventions
Uncoated GAL-101 Salt 1170 mgDrug
Uncoated GAL-101 salt obtained from the capsule contents, mixed with apple sauce and administered orally\_1170mg
PlaceboDrug
Matching placebo administered orally under blinded conditions.
Enteric-Coated Capsules 195 mgDrug
195 mg
Enteric-Coated Capsules 390 mgDrug
390 mg
Uncoated GAL-101 Salt 780 mgDrug
780 mg
Enteric-Coated Capsules 1755 mgDrug
1755 mg
Enteric-Coated Capsules 780 mgDrug
780 mg
Enteric-Coated Capsules 1170 mgDrug
1170 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse EventsTime frame: From the first dose through 28 days after the participant's last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FARMOVS
Bloemfontein, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.